IRIS
GROSSI, Laurino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.252
EU - Europa 4.742
AS - Asia 4.266
SA - Sud America 487
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 4
Totale 15.814
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.174
SG - Singapore 1.568
CN - Cina 1.385
UA - Ucraina 820
IT - Italia 804
IE - Irlanda 725
TR - Turchia 579
SE - Svezia 565
GB - Regno Unito 532
FR - Francia 422
BR - Brasile 394
IN - India 369
DE - Germania 314
VN - Vietnam 193
FI - Finlandia 179
RU - Federazione Russa 135
AT - Austria 64
PL - Polonia 56
CA - Canada 36
MX - Messico 35
AR - Argentina 32
NL - Olanda 27
BD - Bangladesh 24
EC - Ecuador 23
IQ - Iraq 23
KR - Corea 21
EU - Europa 20
BE - Belgio 18
HK - Hong Kong 17
RO - Romania 16
ZA - Sudafrica 16
ES - Italia 15
JP - Giappone 15
ID - Indonesia 13
LT - Lituania 11
IL - Israele 10
MA - Marocco 9
CL - Cile 8
CO - Colombia 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
PK - Pakistan 7
PY - Paraguay 7
CZ - Repubblica Ceca 6
GR - Grecia 6
KE - Kenya 5
TW - Taiwan 5
AL - Albania 4
BA - Bosnia-Erzegovina 4
SA - Arabia Saudita 4
AU - Australia 3
CH - Svizzera 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
IR - Iran 3
JO - Giordania 3
NO - Norvegia 3
OM - Oman 3
UY - Uruguay 3
UZ - Uzbekistan 3
VE - Venezuela 3
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PA - Panama 2
PS - Palestinian Territory 2
AP - ???statistics.table.value.countryCode.AP??? 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
MU - Mauritius 1
MY - Malesia 1
NP - Nepal 1
PT - Portogallo 1
PW - Palau 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 15.814
Salva come PNG Salva come JPEG
Città #
Singapore 1.050
Jacksonville 943
Chandler 779
Dublin 717
Dearborn 468
Southend 378
Princeton 354
Beijing 329
Dallas 298
Nanjing 284
Izmir 272
Ashburn 266
Wilmington 254
Los Angeles 198
Cambridge 157
Woodbridge 119
Buffalo 118
Ann Arbor 115
Tongling 104
Santa Clara 102
Nanchang 93
The Dalles 93
New York 87
Boardman 66
Ho Chi Minh City 66
Houston 65
Council Bluffs 62
Hefei 56
Hebei 53
Vienna 52
Shenyang 48
Altamura 47
Munich 47
Redondo Beach 46
Rome 46
Kunming 45
Tianjin 43
São Paulo 42
Jiaxing 40
Kraków 35
Pescara 35
Hanoi 31
Chieti 29
Hangzhou 27
Bologna 25
Brooklyn 25
Norwalk 25
Dong Ket 22
Düsseldorf 20
Jinan 20
Changsha 19
Milan 19
Ancona 18
Orange 18
Warsaw 18
Brussels 17
Seoul 17
Helsinki 16
Hong Kong 16
Washington 16
Bellante 15
Guangzhou 15
Turku 15
Amsterdam 14
Belo Horizonte 14
Boston 14
Chicago 14
Denver 14
Grevenbroich 14
Lanzhou 14
Montreal 14
Phoenix 14
Vinh 14
Baghdad 13
London 13
Nuremberg 13
Tokyo 13
Ankara 12
Frankfurt am Main 12
Guayaquil 12
Fuzhou 11
Seattle 11
Stockholm 11
Charlotte 10
Falls Church 10
Guadalajara 10
Johannesburg 10
Mumbai 10
Rio de Janeiro 10
Brasília 9
Cepagatti 9
Changchun 9
Poplar 9
San Francisco 9
Haiphong 8
Ningbo 8
Turin 8
Atlanta 7
Curitiba 7
Da Nang 7
Totale 9.326
Salva come PNG Salva come JPEG
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 387
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 185
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 164
Ottimizzazione di vedolizumab in RCU con perdita di risposta a infliximab 149
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 146
Blood cardioplegia: could it protect the ischemic-reperfused human myocardium through antioxidant-type mechanisms? 144
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 144
24-hour pancolonic motility using a portable electronic probe in healthy subjects 144
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 142
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 142
Alterazioni non litiasiche del contenuto colecistico 137
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 136
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 133
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 132
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 132
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 128
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 126
Trasmissione di Helicobacter pylori in un modello murino 124
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 123
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 120
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 120
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 120
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 116
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 115
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 115
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 115
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 114
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 112
USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA 112
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 111
Distribuzione transmurale dei sistemi antiossidanti e della perossidazione lipidica nel ventricolo sinistro di coniglio 110
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 110
Detection of Helicobacter pylori in esophagus and saliva in humans 109
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 108
Transmission of Helicobacter pylori in an animal model. 108
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 107
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 107
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 107
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). 107
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 106
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 106
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 105
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 105
A “REAL LIVE” EXPERIENCE OF INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 105
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 104
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 103
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 103
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 103
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 101
Esophageal and gastric motility in patients with gastroesophageal reflux disease 100
EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 100
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 100
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 100
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 100
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 99
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 98
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 98
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 98
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 97
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 97
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 97
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 96
Peppermint oil (Mintoil®) in the treatment or irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. 96
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY 96
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 96
RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE 95
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 94
THERAPY-RELATED ADVERSE EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 94
Prolonged anal sphincter manometry in normal human subjects 93
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 93
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 93
Increase of swallows before the onset of phase III of migrating motor complex in normal human subjects 93
PRUCALOPRIDE INCREASES BASAL LES TONE IN PATIENTS WITH ESOPHAGEAL MOTILITY DISORDERS 93
CLINICAL AND ECONOMIC EFFECT OF SHORT INFLIXIMAB INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTRE STUDY 93
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 92
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 92
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 92
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 92
Registrazione delle 24 ore della motilità del piloro in soggetti normali 91
THERAPY- RELATED ADVERS EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 91
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 90
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMAMTORY BOWEL DISEASE (IG-IBD). 90
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 89
Proximal and Distal Gastric Distension in Normal Subjects and H. pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 89
LA MALDIGESTIONE 89
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 89
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 88
Effect of nitric oxide on propagated clusters of spontaneous motor waves in an ex vivo rabbit intestinal preparation 88
ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE 88
LA MALATTIA DA REFLUSSO GASTROESOFAGEO 88
EFFICACY AND SAFETY OF INFLIXIMAB IN THE LONG-TERM IN CROHN’S DISEASE 88
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 87
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 87
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 87
Role of nitric oxide on peristaltic motor activity in an in vitro rabbit intestinal preparation 87
ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE 87
Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients 87
Relationship between interdigestive esophageal and gastric motility in humans 86
Fabric Phase Sorptive Extraction-High Performance Liquid Chromatography-Photo Diode Array Detection Method for Simultaneous Monitoring of Three Inflammatory Bowel Disease Treatment Drugs in Whole Blood, Plasma and Urine 86
ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS 85
Totale 10.916
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.309
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.309
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021536 0 0 0 0 0 227 18 23 30 135 21 82
2021/2022789 35 15 4 200 46 16 24 66 54 9 88 232
2022/20232.154 188 207 108 264 194 488 145 158 253 41 59 49
2023/20241.002 79 51 62 36 34 292 236 37 14 44 19 98
2024/20252.576 182 423 292 47 54 66 99 173 310 121 252 557
2025/20262.540 488 252 637 543 453 167 0 0 0 0 0 0
Totale 16.109